Effect of Fluvastatin on Brown Fat Activity

Inclusion Criteria: * Male volunteers (18-40 y) * body mass index 19 to 27 kg/m² * Fluent in German or English Exclusion Criteria: * Regular physical exercise of more than \>150 min of exercise per week. * Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product, * Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.), * Clinically indicated intake of the following medications: Corticosteroids, CYP3A4-Inhibitors (Itraconazol, Voriconazol, Fluconazol, Clarithromycin, Erythromycin, Indinavir, Nelfinavir, Ritonavir, Grapefruit juice), Beta-Blocker, Neuroleptics, Tricyclic Antidepressants, * Known or suspected non-compliance, drug or alcohol abuse, * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant, * Participation in another study with investigational drug within the 30 days preceding and during the present study, * Participation in another study involving ionizing radiation in the same year, * Previous enrolment into the current study, * Enrolment of the investigator, his/her family members, employees and other dependent persons, * MRI contraindications: Not MRI-compatible metal in the body, cardiac pacemaker, History of surgery with possible metal clips/parts still in the body, claustrophobia. * Resting pulse rate \> 70 bpm * Known arterial hypertension or resting blood pressure \> 130/80 mmHg. * frequence corrected QT-time (QTc) \>430 ms * Serum creatinine \> 1.5x upper limit of norm (ULN), i.e.\> 145 µmol/L * creatine kinase \> 1.5x ULN, i.e. \> 300 U/L * aspartate transaminase (ASAT) \> 1.5x ULN, i.e. \> 51 U/L * alanine aminotransferase (ALAT) \> 1.5x ULN, i.e. \> 88 U/L * Hypothyroidism * Vitamin D deficiency, Vitamin D3 \< 25 nmol/L * Intake of anticoagulants or inhibitors of platelet aggregation (e.g. Aspirin, clopidogrel). * Known tendency to form keloids (hypertrophic scar tissue)